Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs Lisata Therapeutics (LSTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biodexa Pharmaceuticals American Depositary Shs is the larger company by market cap ($982,950 vs $647,451), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDRX | LSTA |
|---|---|---|
| Share price | $1.88 | $0.8989 |
| Market cap | $982.95K | $647.45K |
| 1-day change | -3.85% | -1.22% |
| YTD return | — | -51.67% |
| 1-year return | — | -54.14% |
| 5-year return | — | -93.89% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $509.89 | $-28.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $170.00K |
| Revenue growth (YoY) | — | -83.00% |
| Net income (latest FY) | — | $-16.59M |
| Operating margin | — | -10711.18% |
| Net margin | — | -9756.47% |
| 52-week high | $357.60 | $76.05 |
| 52-week low | $1.85 | $0.85 |
| Distance from 52-week high | -99.48% | -98.82% |
| Analyst consensus | none | none |
| Avg. price target upside | +375.20% | — |
| Average volume | 618.91K | 13.46K |
| Shares outstanding | 524.24K | 720.27K |
| Employees | 11 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
BDRX vs LSTA FAQ
Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or Lisata Therapeutics?
Biodexa Pharmaceuticals American Depositary Shs (BDRX) is larger, with a market capitalization of $982.95K compared with $647.45K for Lisata Therapeutics (LSTA).
Are Biodexa Pharmaceuticals American Depositary Shs and Lisata Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.